drugset

drugset / Trial / NCT03201913

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

NCT03201913 ↗

Phase 1 Completed 15 enrolled TTC Oncology, LLC

NaSingle-groupOpen-labelTreatment

Summary

Phase1 study of TTC 352 for treatment of metastatic ER+ breast cancer.

Timeline

Start: 2017-12-11
Primary completion: 2019-12-31
Completion: 2020-04-30

Publications

Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Res Treat. 2020 Oct;183(3):617-627. doi: 10.1007/s10549-020-05787-z. Epub 2020 Jul 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TTC-352	Small molecule	—	Oral

Indications